Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Cogent Biosciences's 3-Year RORE % for the quarter that ended in Sep. 2024 was 0.29%.
The industry rank for Cogent Biosciences's 3-Year RORE % or its related term are showing as below:
COGT's 3-Year RORE % is ranked better than 63.8% of 1370
companies
in the Biotechnology industry
Industry Median: -9.185
vs COGT: 0.29
Cogent Biosciences 3-Year RORE % Historical Data
The historical data trend for Cogent Biosciences's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cogent Biosciences's 3-Year RORE %
For the Biotechnology subindustry, Cogent Biosciences's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences's 3-Year RORE % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's 3-Year RORE % falls into.
Cogent Biosciences 3-Year RORE % Calculation
Cogent Biosciences's 3-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 3-year before.
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Cogent Biosciences 3-Year RORE % Related Terms
Thank you for viewing the detailed overview of Cogent Biosciences's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
COGT has been successfully added to your 